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Abstract
Background: Latexin, also known as endogenous carboxypeptidase inhibitor (CPI), has been found to inhibit
mouse stem cell populations and lymphoma cell proliferation, demonstrating its potential role as a tumor
suppressor. Our previous study also suggested a correlation between latexin expression and malignant
transformation of immortalized human gastric epithelial cells. Here, we examined latexin expression in human
gastric carcinomas and investigated the effect of differential latexin expression on proliferation of gastric cancer
cells in vitro and in vivo.
Methods: Monoclonal antibody against human latexin was prepared and immunohistochemical analysis was
performed to detect latexin expression in 41 paired gastric carcinomas and adjacent normal control tissues. Human
gastric cancer cells MGC803 (latexin negative) stably transfected with LXN gene and BGC823 cells (latexin positive)
stably transfected with antisense LXN gene were established for anchorage-dependent colony formation assay and
tumorigenesis assay in nude mice. Differentially expressed genes in response to exogeneous latexin expression
were screened using microarray analysis and identified by RT-PCR. Bisulfite sequencing was performed to analyze
the correlation of the methylation status of LXN promoter with latexin expression in cell lines.
Results: Immunohistochemical analysis showed significantly reduced latexin expression in gastric carcinomas (6/41,
14.6%) compared to control tissues (31/41, 75.6%) (P < 0.05). Overexpression of LXN gene in MGC803 cells
inhibited colony formation and tumor growth in nude mice. Conversely, BGC823 cells transfected with antisense
LXN gene exhibited enhanced tumor growth and colony formation. Additionally, several tumor related genes,
including Maspin, WFDC1, SLPI, S100P, and PDGFRB, were shown to be differentially expressed in MGC803 cells in
response to latexin expression. Differential expression of Maspin and S100P was also identified in BGC823 cells
while latexin expression was downregulated. Further bisulfite sequencing of the LXN gene promoter indicated CpG
hypermethylation was correlated with silencing of latexin expression in human cells.
Conclusions: Latexin expression was reduced in human gastric cancers compared with their normal control
tissues. The cellular and molecular evidences demonstrated the inhibitory effect of latexin in human gastric cancer
cell growth and tumorigenicity. These results strongly suggest the possible involvement of latexin expression in
tumor suppression.
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Latexin was originally identified in the lateral neocortex
of rats and serves as a marker of regionality and devel-
opment in rodent nervous systems [1]. Latexin has also
been found expressed in various types of human and
other vertebrates tissues [2,3]. Human LXN gene [Gen-
Bank: NM_020169] encodes latexin protein comprised
of 222 amino acids with 84.2% identical to rat, and
84.7% identical to mouse latexin proteins [3]. Human
latexin consists of two topologically equivalent subdo-
mains linked by an a-helix and has been found to act as
a non-competitive inhibitor of vertebrate carboxypepti-
d a s eAa n dB( C P Aa n dC P B )[ 4 , 5 ] .H o w e v e r ,i t s
sequence is unrelated to any other reported carboxypep-
tidase inhibitor (CPI), but shows significant homology
with the putative tumor suppressor, tazarotene-induced
gene 1 (TIG1), suggesting a familial relationship [6,7].
Although the biochemical function of latexin as an
endogenous CPI has been clearly demonstrated, there
are only few reports about the physiological activities of
this protein in mammalian cells and the underlying
mechanisms remain unclear.
Latexin is the only known inhibitor of CPA in mam-
mals. Human serum CPA activity has been reported to
be a potential biomarker for early-stage pancreatic carci-
noma, indicating a possible role of latexin in tumorigen-
esis [8]. Notably, one recent study by Liang and
colleagues revealed that latexin functions in the negative
control of the hematopoietic stem cell (HSC) popula-
tions in mice by decreasing cell replication and increas-
ing apoptosis [9]. Elevated latexin expression has also
been reported in normal human stem cells compared to
the same cell populations from patients with acute mye-
logenous leukemia (AML) or lymphoma. The ectopic
expression of latexin in mouse lymphoma cells lacking
latexin expression show remarkable suppression of
growth in vitro [10]. Latexin has been suggested to
function as a potential tumor suppressor which reduces
the risk of old stem cells transforming into cancer stem
cells [11].
In a previous study, we identified high levels of latexin
expression in an immortalized human gastric epithelium
cell line, GES-1 as compared to expression in the MC
cell line, which is the malignant derivative of the GES-1
cell line [12]. These findings suggest that downregula-
tion of latexin expression is correlated with malignant
transformation of immortalized human gastric epithelial
cells. To further investigate latexin expression in human
tumors, we collected 41 paired gastric carcinomas and
adjacent normal tissues and performed immunohisto-
chemical analysis for latexin expression using an anti-
latexin monoclonal antibody. Additionally, human gas-
tric cancer cells with stably increased or decreased
latexin expression were established and used to examine
the effect of latexin expression on tumor cell growth
and tumorigenesis. Moreover, differential expression of
genes induced by ectopic latexin expression in cancer
cells were screened by microarray analysis, and correla-
tion of LXN promoter methylation with latexin expres-
sion was analyzed in human cells.
Methods
Cell culture
The GES-1 cell line is an immortalized human gastric
epithelial cell which was established by infecting primary
fetal gastric epithelial cells with SV40 virus. The MC cell
line was derived from GES-1 cells which survived after
treatment with the carcinogen N-methyl-N’-nitro-N-
nitrosoguanidine (MNNG), and exhibited tumorigenic
capability in nude mice [12]. The human gastric adeno-
carcinoma cell lines MGC803 and BGC823 were
obtained from the People’s Hospital of Peking Univer-
sity, Beijing, P. R. China. All other cell lines including
three immortalized human epithelial cell lines and eight
human cancer cell lines were purchased from ATCC
(American Type Culture Collection). All cells were
maintained in Dulbecco’s modified Eagle’sm e d i u m
(DMEM) supplemented with 10% FBS (Gibco, Grand
Island, NY), 100 U/ml penicillin and 100 U/ml strepto-
mycin (Invitrogen, Carlsbad, CA) at 37°C in a humidi-
fied incubator with 5% CO2.
Preparation of monoclonal antibody against human
latexin
Glutathione S-transferase (GST) and GST-latexin fusion
proteins were produced by IPTG induction and purified
with Glutathione Sepharose 4B (GE Healthcare, Buckin-
ghamshire, UK) according to the manufacturer’s instruc-
tions. Mouse immunization, cell fusion and HAT
selection were carried out as previously described [13].
Three hybridomas were obtained, and one of them,
1G11, was used in this study. 1G11 cells were injected
intraperitoneally into BALB/c mice to obtain ascites
fluid. Antibody was purified from the ascites fluid with
ammonium sulfate precipitation and use of a protein A
Sepharose-4B affinity gel (GE Healthcare).
Cytoplasmic and nuclear protein preparation and Western
blot analysis
For each cell line, 2 × 10
6 cells were harvested and cyto-
plasmic and nuclear proteins were extracted using the
NE-PER Nuclear and Cytoplasmic Extraction kit (Pierce,
Rockford, IL) according to the manufacturer’sp r o t o c o l .
For Western blot assay, the cytoplasmic and nuclear
proteins were separated by 12% SDS-PAGE and trans-
ferred to nitrocellulose membranes (Millipore, Billerica,
MA). The membranes were then blocked with 5% non-
fat milk and probed with anti-latexin antibody, 1G11
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PBS buffer three times, membranes were incubated with
horseradish peroxidase-conjugated anti-mouse IgG
(Santa Cruz Biotechnology, Santa Cruz, CA) and visua-
lized using the enhanced chemiluminescence system,
ECL (GE Healthcare).
Tissue samples and immunohistochemical staining
To examine the expression of latexin in human tumor
tissues, 41 paired gastric carcinomas and adjacent nor-
mal tissue counterparts were used in this study. All tis-
sues were paraffin-embedded and were obtained from
the Beijing Cancer Hospital & Institute (Beijing, P.R.
China). The slides were deparaffinized and treated with
1% hydrogen dioxide to block endogenous peroxidase.
Heat induced epitope retrieval was performed. After
preincubating in 0.2% Tween 20/PBS buffer containing
5% dry milk, slides were incubated with anti-latexin
monoclonal antibody-1G11 (see description above, 1:100
dilution) at 4°C overnight. After rinsing, biotinylated
secondary antibody and horseradish peroxidase labeled
streptavidin were added. The signal was developed with
DAB-H2O2 solution, and slides were counterstained
with 5% hematoxylin. The brown cytoplasmic signals
represent positive staining for latexin. This study was
approved by both the Ethics and the Academic commit-
tees of Peking University School of Oncology, and
informed consent was obtained from each subject.
Transfection and stable colony selection
Transfection was performed using Lipofectamine 2000
(Invitrogen) based on the manufacturer’s instructions. In
brief, human gastric cancer cells MGC803 (latexin nega-
tive) and BGC823 cells (latexin positive) were seeded in
60 mm-dishes (5 × 10
5 cells per dish) and incubated
over night. MGC803 cells were then transfected with
pcDNA4/TO-LXN or pcDNA4/TO empty vector (Invi-
trogen), while BGC823 cells transfected with pLXSN-
antisense-LXN or pLXSN empty vector (Clontech).
Twenty-four hours after transfection, cells were pas-
saged into 10 cm-dishes at 1:20 dilution, and G418 (400
μg/ml, Invitrogen) was added to the growth medium on
the following day. The G418 concentration was reduced
to 200 μg/ml 5 d after selection, and selection medium
was replaced every 3-4 d until individual clones could
be identified. After 3 weeks of selection, at least forty
G418 resistant clones of MGC803 or BGC823 cells were
identified and re-cultured with selective medium. Total
protein was extracted and evaluated by Western blot
using anti-latexin monoclonal antibody, 1G11. Two
clones derived from MGC803 cells stably expressing
latexin (C39-8 and C46) and two clones from BGC823
cells with downregulated latexin expression (C3 and C7)
were selected for further experiments.
Colony formation assay
To examine the effect of upregulated or downregulated
latexin expression on proliferation of gastric cancer
cells, C39-8 and C46 cells with MGC803 cells trans-
fected with pcDNA4/TO empty vector as control, and
C3 and C7 cells with BGC823 cells transfected with
pLXSN empty vector as control were used for colony
formation assay. Each kind of cell was seeded into 6-
well plates (1,000 cells/well) and cultured for 2 weeks in
medium containing 200 μg/ml G418. These cultures
were washed twice with PBS, fixed with a mixture of
25% acetic acid and 75% methanol at room temperature
for 15 min, and then stained with 0.4% crystal violet.
Clones larger than 2 mm were counted and the number
of clones per well was averaged from three wells for
each experiment, and three independent experiments
were performed.
Tumorigenicity assay in nude mice
Tumorigenicity assay was performed as previously
described [14]. Male BALB/c nude mice (6-7 weeks old)
were obtained from the Department of Laboratory Ani-
mal Science, Peking University Health Science Center.
Cells with upregulated or downregulated latexin expres-
sion or control cells were injected subcutaneously into
the lateral root of one posterior limb of a nude mouse
(1 × 10
6 cells/mouse, 8 mice in each experimental
group). Tumor size was measured every third day after
injection. Tumor volume was calculated according to
the formula V =( a × b
2)/2, where a = the largest super-
ficial diameter and b = the smallest superficial diameter.
Three weeks postinjection, mice were sacrificed and
photographed. Care of experimental animals was in
accordance with institutional animal care and use com-
mittee guidelines.
Microarray analysis and RT-PCR identification
Total RNA was isolated from C39-8 cells expressing
latexin or control MGC803 cells using Trizol reagent
(Invitrogen) according to the manufacturer’si n s t r u c -
tions. Oligonucleotide array analysis was performed by
the CapitalBio Corp. (Beijing, P.R. China) using a 22K
Human Genome Array (Cat. No. 220010) consisting of
70-mer probes and representing 21,522 human gene
transcripts as previously described [15]. Data processing
and normalization were performed according to stan-
dard procedures using a LOWESS program. The raw
microarray data were released into the GEO-database
(accession number GSE15787).
To confirm these microarray results, 9 differentially
expressed genes were selected for further semi-quantita-
tive reverse transcription-polymerase chain reaction
(RT-PCR) testing. Total cellular RNA was reverse tran-
scribed using SuperScript III Reverse Transcriptase
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tions. The cDNAs obtained were used as template for
amplification with HotStarTaq DNA polymerase (Qia-
gen, Hilden, Germany). For each of the genes examined,
two independent amplifications with 2-cycle intervals (N
and N+2) were performed to ensure the reliability of
RT-PCR results. The primer sets, annealing temperature,
cycles for amplification, and length of PCR products are
listed in Table 1.
Bisulfite sequencing
Cellular genomic DNA was extracted using the standard
phenol-chloroform method. Bisulfite treatment of DNA
was performed as previously described [16]. Each of
bisulfite-modified DNA samples was used as template
and a 762 bp fragment covering the entire exon 1 of
human LXN gene together with a part of the sequence
upstream of exon 1 was amplified with HotStar Taq
DNA polymerase (Qiagen) using the following primers:
forward, 5’-TAAAAAGTTGAGGATGAGTAAG-3’ and
reverse 5’-CCTACTAAACTCACCTCCATAC-3’.P C R
reactions were performed under the following condi-
tions: an initiation denaturation step at 95°C for 15 min,
followed by 34 cycles at 94°C for 30 s, 60°C for 30 s,
and 72°C for 50 s, and a final extension step at 72°C for
10 min. The PCR products were then gel-purified and
cloned into a pGEM-T Easy Vector (Promega, Madison,
WI). Four to 6 individual clones were randomly chosen
for sequencing using an ABI PRISM 3730 DNA sequen-
cer (Perkin-Elmer, Foster, CA).
Results
Human latexin was expressed predominantly in the
cytoplasm
A monoclonal antibody against human latexin was
raised as described in Materials and Methods. To verify
the specificity of the anti-latexin monoclonal antibody,
1G11, Western blot analysis was performed with puri-
fied GST and GST-latexin fusion proteins. 1G11 specifi-
cally recognized GST-latexin but did not bind GST
Table 1 Primers for RT-PCR analysis of differentially expressed genes induced by latexin expression in MGC803 cells
Gene symbol Primers, 5’-3’ Annealing (°C) Cycles (N) Product (bp)
S100P 59 24 161
F CGTGGATAAATTGCTCAAGGAC
R TCTGCCAGGAATCTGTGACATC
PDGFRB 57 30 605
F CTCAGGCCACGATGAAAGTG
R GTCTCTGTGGACGCAGTTC
SLPI 57 22 239
F AACCTGAGTGCCAGAGTGAC
R AACGCAGGATTTCCCACACA
Maspin 57 23 378
F AATGCCAAGGTCAAACTCTCC
R GCATCCACAGAAAAGTCAGG
WFDC1 59 26 314
F GCTATGAGTGCCACATCCTGAG
R ATCTCTGGGGTCTTGCTCTGCT
FBN2 59 25 561
F GAATGCTCCAATCCCAATGC
R GCTGTCATCGTTCCCTTGAG
A2M 57 22 408
F CATTGGCTATCTCAACACTGG
R TGGTCCCCTTCTTGTGCTGTC
BCHE 59 25 520
F CATTACACAGACTGGGTAGATG
R CTTTCCACTCCCATTCTGCTTC
NEP 57 26 404
F CTTCGATGACAATGGCAGAAAC
R GCAAAGTCCCAATAATCCTGA
b-actin 57 21 638
F GGAGAAAATCTGGCACCACAC
R CGTACAGGTCTTTGCGGATGT
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Page 4 of 11(Figure 1A). The expression of latexin in GES-1 and MC
cell lines was then determined by Western blot using
1G11, resulting in the recognition of a 29-kDa protein
with a much higher expression level in the GES-1 cells
than in the MC cells (Figure 1B). Cytoplasmic and
nuclear proteins which were extracted from three
immortalized cell lines (HEK293, HaCaT, GES-1) and
ten cancer cell lines (cervical cancer cells C33A, CaSki,
Hela, and SiHa; gastric cancer cells AGS, SNU-1, N87,
SNU-16, BGC823 and MGC803) were evaluated with
Western blot. As shown in Figure 1C, the expression of
latexin was found predominantly in the cytoplasm of the
three immortalized cell lines and in only three of ten
cancer cell lines.
Latexin expression was decreased in human gastric
carcinomas compared with normal control tissues
The expression level of latexin was much higher in GES-
1 cells than in MC cells, raising the possibility that latexin
expression is downregulated in malignant tissue cells. To
test this possibility, we investigated latexin expression in
41 gastric carcinomas and paired corresponding adjacent
normal tissues by immunohistochemical staining of
tissue sections. Positive latexin expression was shown
as brown staining in the cell cytoplasm as seen in
Figure 2A. Latexin positivity in gastric tissues was calcu-
lated and represented Figure 2B. Among the gastric car-
cinoma tissues tested, only 14.6% (6/41) were latexin
positive, while 75.6% of normal gastric tissues (31/41)
were latexin positive. These findings suggest a correlation
of latexin expression with tumorigenesis of gastric cancer.
Differential expression of latexin in gastric cancer cells
changed the ability of anchorage-dependent colony
formation and tumorigenesis in nude mice
The downregulation of latexin expression in multiple
tumor cell lines and tumor tissues suggests that latexin
may be functionally involved in the suppression of can-
cer cell growth. Evaluation of six gastric cancer cell lines
showed latexin expression in only two cell lines,
BGC823 and N87, but in all other cell lines tested
including MGC803 latexin expression was negative
(Figure 1C). MGC803 and BGC823 cells were widely
used for investigation of tumor cell proliferation, cell-
cycle arrest or apoptosis, tumor cell invasion, and the
involved cellular mechanisms [17-20]. MGC803 and
BGC823 cells were therefore used to evaluate the effect
of latexin expression on tumor cell growth. MGC803
cells were transfected with a latexin expressing plasmid
(pcDNA4/TO-LXN) and BGC823 cells transfected with
an antisense LXN gene expressing plasmid (pLXSN-
antisense-LXN), followed by selection of G418-resistant
Figure 1 Analysis of latexin expression in human immortalized
and cancerous cells. (A) Specificity of 1G11, an anti-latexin
monoclonal antibody, was tested by Western blot. The left panel is
a coomasie stained gel and the right panel shows Western blot
with GST and GST-latexin proteins. Expression of latexin (B) in GES-1
and MC cells and (C) in cytoplasmic (c) and nuclear (n) proteins
extracted from the indicated cells was identified using Western blot
with 1G11 antibody (1:1000 dilution). Actin was used as an internal
control.
Figure 2 Analysis of latexin expression in human gastric
carcinomas. (A) Immunohistochemical staining for latexin with
monoclonal antibody-1G11 (1:200 dilution). The brown signals
represent positive staining for latexin. a, normal gastric tissue; b,
gastric carcinoma. Magnification, × 200. (B) The positivity rates of
latexin were calculated and illustrated as shown. The number of
latexin-positive samples and the total number of each kind of tissue
tested here are shown just above each column.
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Page 5 of 11clones. C39-8 and C46 cells with stable overexpression
of latexin in MGC803 cells (Figure 3A), and C3 and C7
cells with stably downregulated latexin expression in
BGC823 cells (Figure 4A) were obtained and subjected
to colony formation assay. As shown in Figure 3B, over-
expression of latexin in C39-8 and C46 cells resulted in
nearly 70% inhibition of colony formation as compared
with MGC803 cells transfected with empty vector (both
P values < 0.05), and the majority of clones of C39-8
and C46 cells were significantly smaller than those of
control cells. Conversely, downregulated latexin expres-
sion in C3 and C7 cells caused about 4-fold increase of
clones compared to BGC823 cells transfected with
empty vector (both P values < 0.05, Figure 4B).
The effects of latexin expression on the tumorigenic
potential of gastric cancer cells in vivo were also evalu-
ated. To this end, MGC803 cells with overexpression of
latexin (C39-8 and C46), and BGC823 cells with down-
regulated latexin expression (C3 and C7) were injected
subcutaneously into BALB/c nude mice (8 mice/group).
Tumor growth was measured every third day after injec-
tion, and after 3 weeks, mice were sacrificed and
photographed, and tumors were removed and weighed
(Figures 3C and 4C). All 8 nude mice injected with con-
trol MGC803 cells developed grossly visible tumors at
the site of injection within 3 weeks. In comparison, 6
mice injected with C39-8 cells and 7 mice with C46
cells displayed visible tumors during the same period of
time, and both the average tumor weights were signifi-
cantly less than that of the control group (both P values
<0 . 0 5 ) .C o m p a r e dw i t hc o n t r o lB G C 8 2 3c e l l s ,b o t hC 3
and C7 cells showed obviously increased capacity for
tumorigenesis (both P values < 0.05). Taken together,
these results strongly suggest that latexin acts as an
inhibitor of tumor cell growth and tumorigenicity.
Latexin expression induced differential expression of
several tumor related genes in human gastric cancer cells
To study the molecular mechanism for the inhibitory effect
of latexin expression on tumor cell growth, microarray
assay was performed to compare gene expression profiles in
C39-8 cells and control MGC803 cells transfected with
empty vector. The expression of approximately 22,000
genes was tested. Among these, the expression of 18 genes
Figure 3 The effect of ectopic latexin expression on tumor cell growth and tumorigenicity of MGC803 cells. (A) Latexin expression in
gastric cancer cells MGC803 transfected with empty vector (pcDNA4/TO) and MGC803 cells stably overexpressing latexin (C39-8 and C46) was
tested by Western blot using 1G11 antibody (1:1000 dilution). (B) C39-8, C46, and control MGC803 cells were used for anchorage-dependent
colony formation assay. The photographs show colonies formed by each stable transfectant 2 weeks after plating. Assays were performed in
triplicate and the average numbers of clones from one whole well are shown in the graph. (C) C39-8, C46, and control cells were injected
subcutaneously into BALB/c nude mice (8 mice/group). The graph (left panel) represents tumor volume as measured on the indicated days.
Tumors were excised 21 days after injection (middle panel) and the average weight of tumors of each group was shown as columns (right
panel), with bars representing Standard Deviation.
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Page 6 of 11was increased while the expression of another 19 genes was
decreased 2 to 11 fold in C39-8 cells in comparison with
the control MGC803 cells (Tables 2 and 3). To validate
these results, 9 differentially expressed genes were subjected
to semi-quantitive RT-PCR analysis. As shown in Figure
5A, four of these, including S100P, PDGFRB, SLPI, and
BCHE were found to be downregulated, while 5 genes
including Maspin, WFDC1, FBN2, A2M, and NEP were
upregulated in C39-8 cells compared with control MGC803
cells. C46 cells were also detected and showed the similar
expression changes as C39-8 cells for these 9 genes tested.
Further RT-PCR analysis of C3 and C7 cells revealed
that S100P expression was upregulated, and Maspin,
FBN2, and A2M expression downregulated by decreased
latexin expression in BGC823 cells (Figure 5B). While no
obvious expression changes of SLPI and WFDC1, and no
expression of PDGFRB, BCHE, and NEP were detected in
C3 and C7 cells in comparison with control BGC823 cells.
CpG methylation regulated transcriptional silencing of
LXN gene in human cells
The methylation of the LXN gene promoter region was
evaluated in various cell lines. A 762 bp fragment which
spans exon 1 and the region extending approximately
400 bp upstream of exon 1 of LXN gene [GenBank:
NT_005612] is rich in CpG islands, and a total of
26 CpG sites are included in this region as shown
in Figure 6A. The sequence analysis of the bisulfite-
modified DNA revealed extensive hypermethylation (96-
97%) of CpG sites in four cell lines which showed no
detectable latexin expression, whereas hypomethylation
(11-20%) was detected in five latexin expressing cell
lines (Figures 6B and 6C), suggesting that CpG hyper-
methylation induces transcriptional silencing of LXN
gene in human cells. In addition, more than 99% non-
CpG cytosines were converted into uracil after bisulfite
treatment in this experiment, showing that bisulfite mod-
ification of genomic DNA was carried out successfully.
Discussion
The physiological activity of latexin has been studied
relatively little and its effect on cell growth is only now
being discovered. In this study, we developed an anti-
latexin monoclonal antibody and found that this anti-
body specifically recognizes a 29-kDa protein, latexin.
Western blot analysis of cytoplasmic and nuclear
Figure 4 The effect of downregulated latexin expression on tumor cell growth and tumorigenicity of BGC823 cells. (A) Gastric cancer
cells BGC823 were transfected with an antisense LXN gene expressing vector (pLXSN-antisense-LXN) and two G418-resistant colonies (C3 and
C7) with stably decreased latexin expression were selected and tested by Western blot using 1G11 antibody (1:1000 dilution). BGC823 cells
transfected with empty pLXSN vector were used as control. (B) C3, C7, and control BGC823 cells were used for colony formation assay. Assays
were performed in triplicate and the average numbers of clones were calculated and shown in the graphs. (C) C3, C7, and control BGC823 cells
were injected subcutaneously into BALB/c nude mice (8 mice/group). The left graph shows tumor volume as measured on the indicated days.
Tumors were excised 21 days after injection (middle panel) and the average weight of tumors of each group was shown as columns (right
panel), with bars representing Standard Deviation.
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Page 7 of 11proteins revealed that latexin was located predominantly
in the cytoplasm of human cells, and was detected in all
three kinds of human immortalized cells and in three of
ten human cancer cells tested in this work. Immunohis-
tochemical analysis demonstrated that latexin was
expressed in the cytoplasm of tissue cells. Among the
gastric carcinoma tissues tested, only 14.6% (6/41) were
latexin positive, while 75.6% of normal gastric tissues
(31/41) were latexin positive (P < 0.05), indicating a
correlation of latexin expression with tumorigenesis of
gastric cancer. To study the effect of latexin expression
on cancer cell growth and tumorigenicity, a LXN gene
expression vector was introduced into the latexin-defec-
tive human gastric cancer cells MGC803, and two clones
(C39-8 and C46) with stable latexin expression were
selected and used for colony formation assay and tumor
growth assay in nude mice. Both C39-8 and C46 cells
exhibited suppressed tumorigenicity and proliferation as
Table 3 Downregulated genes induced by latexin expression in human gastric cancer cells MGC803
Gene symbol Description RefSeq Relative fold decrease
CGA Chorionic gonadotropin-alpha chain NM_000735 5.9
FBXO2 F-box only protein 2 NM_012168 3.7
MCTP1 Multiple C2-domains with 2 transmembrane regions 1 NM_024717 3.6
BCHE Butyrylcholinesterase NM_000055 3.4
CRABP2 Retinoic acid-binding protein II, cellular NM_001878 3.0
DKK1 Dickkopf related protein-1 precursor NM_012242 2.7
TLR9 Toll-like receptor 9 NM_017442 2.6
KIAA1046 Putative HIV-1 induced protein HIN-1 NM_199324 2.6
PIR121 Cytoplasmic FMRP interacting protein 2 NM_014376 2.5
SLPI Secretory leukocyte protease inhibitor NM_003064 2.3
TNFAIP8 Tumor necrosis factor-a-induced protein 8 NM_014350 2.3
JDP1 J domain containing protein 1 NM_021800 2.3
KCNJ2 Inward rectifier potassium channel 2 NM_000891 2.3
P2RY6 P2Y purinoceptor 6 NM_176798 2.3
S100P S100 calcium-binding protein NM_005980 2.2
PDGFRB Platelet-derived growth factor receptor-beta NM_002609 2.2
LCCP Leman coiled-coil protein NM_016201 2.1
RGC32 Response gene to complement 32 NM_014059 2.0
KRT18 Cytokeratin 18 NM_199187 2.0
Table 2 Upregulated genes induced by latexin expression in human gastric cancer cells MGC803
Gene symbol Description RefSeq Relative fold increase
A2M Alpha 2 macroglobulin NM_000014 10.3
NEP Neprylisin NM_007289 5.0
FBN2 Fibrillin-2 NM_001999 4.5
DPT Dermatopontin NM_001937 3.3
Maspin Mammary serine protease inhibitor NM_021197 3.1
AKR1C1 Aldo-keto reductase family 1, member C1 NM_002639 2.9
WFDC1 Wap-type four disulfide core 1 NM_001353 2.6
ABCC3 ATP-binding cassette, sub-family C NM_002639 2.5
HXB Hexabrachion NM_002160 2.5
SC4MOL Sterol-C4-methyl oxidase-like NM_006745 2.5
COL7A1 Collagen, type VII, alpha 1 NM_000094 2.4
COP CARD only protein NM_052889 2.3
PEG10 Paternally expressed 10 XM_496907 2.2
CSRP2 Cysteine and glycine-rich protein 2 NM_001321 2.1
C4BPA Complement component 4 binding protein, alpha NM_000715 2.1
FLJ23153 Tumor necrosis-a-induced adipose-related protein NM_024636 2.1
PLSCR1 Phospholipid scramblase 1 NM_021105 2.1
INSIG1 Insulin-induced protein 1 NM_198336 2.1
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Page 8 of 11compared to control MGC803 cells, suggesting exogen-
ous expression of latexin in MGC803 cells inhibited can-
c e rc e l lg r o w t h .T of u r t h e re x a m i n ew h e t h e ro rn o tt h e
same results will be obtained in other cancer cells, a
latexin-positive gastric cancer cell line BGC823 was
transfected with an antisense LXN gene expression vec-
tor and two clones (C3 and C7) with stably downregu-
lated latexin expression were selected. Inhibition of
latexin expression in both C3 and C7 cells accelerated
tumor cell growth in vitro a n di nn u d em i c ec o m p a r e d
with control BGC823 cells, indicating that decreased
latexin expression may contribute to tumorigenesis of
gastric carcinoma. As latexin is expressed in normal
human tissues of various origins, it is possible that latexin
expression may also repress the growth of tumors in
other organs.
To investigate the underlying molecular mechanism for
the role of latexin expression in negative control of tumor
cell growth, we examined the changes in the gene expres-
sion profile in response to latexin expression in C39-8
cells compared with MGC803 cells transfected with empty
vector. Several genes previously demonstrated to be asso-
ciated with malignant phenomena were identified by
microarray assay and confirmed by RT-PCR. Among
these, mammary serine protease inhibitor (Maspin) and
wap-type four disulfide core 1 (WFDC1) are tumor sup-
pressor candidates with protease inhibitor activity. Down-
regulation of Maspin and WFDC1 has been found in a
variety of cancers [21-23]. Consistent with its tumor sup-
pressor potential, ectopic expression of latexin in C39-8
cells increased expression levels of Maspin or WFDC1 by
more than 2 or 3 fold separately. In contrast, secretory leu-
kocyte protease inhibitor (SLPI) which is also a protease
inhibitor but functions to enhance cancer invasion [24]
was downregulated by latexin expression to less than one
half of control level. In addition, there were two other
genes, S100 calcium-binding protein (S100P) and platelet-
derived growth factor receptor-beta (PDGFRB), whose
expression level was downregulated by latexin expression
by more than 2 fold. S100P protein regulates calcium sig-
nal transduction and mediates cytoskeletal interaction,
protein phosphorylation and transcriptional control.
Increased level of S100P expression has also been found to
correlate with poor survival in breast and lung cancer, and
with progression to metastatic disease in pancreatic cancer
[25] and prostate cancer [26]. Platelet-derived growth fac-
tors (PDGFs) and their tyrosine kinase receptors
(PDGFRA and B) play essential roles in stimulating cell
growth and differentiation, and these molecules have been
demonstrated to be involved in growth stimulation of
tumor cells, tumor angiogenesis and invasiveness [27,28].
Further evaluation of these genes in C46 cells showed the
similar expression changes with C39-8 cells, in compari-
son with control MGC803 cells. Thus, alterations of
expression of these genes influenced by latexin expression
strongly support the concept that latexin exerts a growth
inhibitory function in tumor cells. The expression of these
identified genes was also analyzed in C3 and C7 cells
which were derived from BGC823 cells by knocking down
latexin expression. RT-PCR r e s u l t ss h o w e dt h a tS 1 0 0 P
expression was upregulated and Maspin expression down-
regulated by decreased latexin expression in both C3 and
C7 cells compared with control BGC823 cells. These
results are consistent with the regulatory effect of latexin
expression on these two genes found in C39-8 and C46
cells and support the positive effect of downregulated
latexin expression on tumor cell growth. Significant
Figure 5 RT-PCR identification of differential gene expression
induced by latexin expression in gastric cancer cells. To validate
the results of Microarray analysis, 9 differentially expressed genes in
MGC803 cells in response to latexin expression were subjected to
RT-PCR analysis. (A) MGC803 cells stably overexpressing latexin (C39-
8 and C46) and control MGC803 cells transfected with empty vector
were used for analysis. Lane 1 represents negative control using
isolated cellular RNA as PCR template. Lanes 2, 3, and 4 represent
amplification using reverse transcripts derived from control MGC803
cells, C39-8, and C46 cells, respectively. (B) The expression of these
identified genes was also analyzed in latexin knockdown BGC823
cells, C3 and C7. Lane 1 represents negative control. Lanes 2, 3, and
4 represent amplification results of control BGC803 cells, C3, and C7
cells, separately. For each target gene tested, N and N+2 cycles of
RT-PCR amplification were performed to ensure that the PCR
reactions fall within the linear range of amplification. The number of
cycling (N) for each target gene was shown in Table 1. b-actin was
used as the internal control.
Li et al. BMC Cancer 2011, 11:121
http://www.biomedcentral.com/1471-2407/11/121
Page 9 of 11expression changes of SLPI, WFDC1, and PDGFRB were
observed in MGC803 cells in response to overexpression
of latexin, but not in BGC823 cells while latexin expres-
sion was downregulated, which may be caused by the rela-
tively limited decrease of latexin expression level in
BGC823 cells transfected with antisense LXN gene.
The mechanism by which the LXN gene expression is
suppressed in cancer cells has not been demonstrated. It
has been established that cytosine hypermethylation of
the promoter region results in inactivation of numerous
genes in various types of cancers [29,30]. In this study,
cytosine methylation status of the LXN gene promoter
and the initial exon was examined, and hypermethyla-
tion of CpG islands was found to be highly correlated
with the transcriptional silencing of LXN gene in nine
human cell lines tested. Since downregulated expression
of LXN gene was detected in human gastric carcinoma
tissues as compared with adjacent normal tissues, the
CpG methylation status of the LXN gene in the DNA of
paired normal and tumor tissues warrants further
investigation.
Conclusions
We prepared monoclonal antibody against human
latexin and found the reduced latexin expression in
human gastric carcinomas as compared with normal
control tissues. Stable transfection of the LXN gene in
human gastric cancer cells MGC803 attenuated cell
growth in vitro and in vivo. In contrast, gastric cancer
cells BGC823 transfected with antisense LXN gene
expression vector exhibited enhanced capacity for
colony formation and tumorigenicity in nude mice. Con-
sistent with its tumor suppressor potential, ectopic
expression of latexin induced differential expression of
several tumor related genes, including Maspin, WFDC1,
SLPI, S100P, and PDGFRB, in gastric cancer cells. In
addition, latexin expression in human cells was indicated
to be deeply correlated with CpG methylation status of
promoter region. Taken together, our results strongly
suggest that latexin is a potential tumor suppressor.
These findings may open a door for understanding the
physiological activity of latexin and related molecular
mechanisms in regulation of cell growth.
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